AstraZeneca said it is yet to be fully determined whether the vaccine protects against severe disease caused by the highly transmissible coronavirus variant found in South Africa.
AstraZeneca said it had not been able to properly ascertain the effect of the vaccine on severe disease and hospitalisation caused by the South African variant.
Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future.
"In order to respond to an increased global demand, we plan to manufacture two billion doses of our Covid-19 vaccine in 2021 by expanding the previously expected output of 1.3 billion doses by more than 50 per cent," BioNTech said in a statement
The initiative is a collaboration between the governments of Malaysia and China to generate scientific data in the development of the vaccine candidate to evaluate its safety and efficacy against Covid-19 infection
NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, investigators and regulators
Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
We are encouraged by these new data, which reinforce our confidence that the Moderna Covid-19 vaccine should be protective against these newly detected variants," Stephane Bancel, Chief Executive Officer of Moderna, said in a statement.